[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"liver-cancer-primary-and-metastatic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:liver-cancer-primary-and-metastatic":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,75,97,120,144,195],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":39,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":74},"100642988","registry-of-minimally-invasive-cancer-treatment-using-spectral-angio-ct-image-guidance-100642988",false,"NCT07636148","Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance","Prospective Registry of Spectral Angio-CT-Guided Interventional Oncology Procedures in Routine Clinical Practice","PreciseOnco","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Undergoing a clinically indicated IO procedure with a percutaneous or transarterial approach for solid tumors;\n* Use of spectral angio-CT image guidance as part of standard care;\n* Written confirmed consent.\n\nExclusion Criteria:\n\n* Patients who are declared incapacitated;\n* Patients suffering from psychic disorders that make a comprehensive judgement impossible.","ALL","18 Years",{"count":20,"type":21},2000,"ESTIMATED","3 Years","OBSERVATIONAL","This study collects data from patients undergoing minimally invasive, image-guided cancer treatments at participating hospitals in the Netherlands and France. All treatments are performed as standard clinical care and include procedures such as tumor ablation and catheter-based treatments of cancer in the liver, kidney, lung, and bone.\n\nDuring these procedures, a spectral angio-CT system is used for image guidance. This advanced CT scanner automatically captures additional imaging information beyond what is used in routine clinical decision-making. The goal of this study is to investigate how this additional imaging information is associated with treatment outcomes, and how it can be used in the future to improve treatment planning, procedural guidance, and prediction of treatment results.\n\nNo experimental interventions are performed. Participation does not alter the treatment or follow-up patients receive. Data are collected from medical records and imaging systems and stored securely for analysis.",[26,27,28,29,30,31,32,33,34,35,36,37,38],"Liver Cancer (Primary and Metastatic)","Lung Cancer (Diagnosis)","Bone Cancer Metastatic","Bone Cancer Tumor","Kidney Tumors","Renal Cancer","Hepatocellular Carcinoma (HCC)","Renal Cell Carcinoma (Kidney Cancer)","Renal Cell Carcinoma (RCC)","Musculoskeletal Cancers","Musculoskeletal Tumors","Bone Tumors","Lung Tumors",[40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61],"Spectral CT","Dual-layer detector CT","Angio-CT","Image-guided therapy","Interventional oncology","Thermal ablation","Radiofrequency ablation","Microwave ablation","Cryoablation","Transarterial chemoembolization","Transarterial radioembolization","Transarterial embolization","Local tumor control","Tumor recurrence","Progression-free survival","Hepatocellular carcinoma","Liver metastases","Renal cell carcinoma","Lung tumors","Musculoskeletal tumors","Registry","Multicenter","NOT_YET_RECRUITING","2026-06-03",{"date":65,"type":66},"2026-06-09","ACTUAL",{"date":68,"type":21},"2026-07-01",{"date":70,"type":21},"2030-12-31",{"name":72,"class":73},"Mark C Burgmans, MD PhD","OTHER",3,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":83,"studyType":23,"phases":4,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":96},"100637676","prospective-clinical-database-construction-for-liver-cancer-diagnosis-and-treatment-100637676","NCT07587216","Prospective Clinical Database Construction for Liver Cancer Diagnosis and Treatment","Inclusion Criteria:\n\n* Male or female aged ≥18 years at the time of signing the informed consent form\n* Clinically or histologically confirmed diagnosis of liver cancer\n* Recieving treatment and follow-up in Tongji Hospital\n\nExclusion Criteria:\n\n\\- Refuse participanting in this study",{"count":82,"type":21},800,"2 Years","This study is a prospective, observational, real-world cohort study. We aim to establish a prospective database in the Department of Hepatobiliary and Pancreatic Surgery, systematically collecting and integrating patients' full-course diagnostic and therapeutic information along with long-term outcomes. This will enable objective evaluation of prognosis and treatment efficacy in real-world clinical practice, while providing a data foundation and evidence support for subsequent optimization of clinical decision-makin",[26],"RECRUITING","2026-06-02",{"date":89,"type":66},"2026-06-04",{"date":91,"type":66},"2026-01-01",{"date":93,"type":21},"2029-12-31",{"name":95,"class":73},"Tongji Hospital",1,{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":106,"phases":107,"briefSummary":101,"conditions":109,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":96},"100628259","clinical-study-on-the-safety-efficacy-and-exploration-of-immune-mechanisms-of-a-combined-multimodal-tumor-therapy-system-for-hepatic-malignancies-100628259","NCT07459309","Clinical Study on the Safety, Efficacy, and Exploration of Immune Mechanisms of a Combined Multimodal Tumor Therapy System for Hepatic Malignancies","Inclusion Criteria:\n\n1. Age 18-80 years, regardless of gender;\n2. Histopathologically confirmed or clinically diagnosed hepatic malignancies, including primary liver cancer and metastatic liver cancer;\n3. Presence of an image-evaluable target lesion for ablation, with the maximum diameter of the target lesion being 3-5 cm;\n4. Patient is intolerant to or refuses surgical resection;\n5. ECOG performance status score ≤ 2, with an expected survival period of greater than 3 months.\n\nExclusion Criteria:\n\n1. Liver function classified as Child-Pugh C, unimprovable with hepatoprotective therapy;\n2. Massive or diffuse hepatocellular carcinoma;\n3. Presence of vascular tumor thrombus or invasion of adjacent organs;\n4. History of esophageal (gastric fundus) variceal rupture and bleeding within 1 month prior to treatment;\n5. Uncorrectable coagulation dysfunction and severe hematological abnormalities, with a high risk of severe bleeding;\n6. Refractory massive ascites, cachexia;\n7. Active infection, especially inflammatory conditions of the biliary system;\n8. Severe functional failure of major organs such as liver, kidney, heart, lung, and brain;\n9. Impaired consciousness, or inability to cooperate with treatment;\n10. Previous systemic treatments (e.g., chemotherapy) with an interval of less than 2 weeks and not having recovered from prior treatment: CTCAE 6.0 grade \\>1 (except for alopecia);\n11. Any other factors deemed by the investigator to make the subject unsuitable for participation or to affect the subject's involvement in the study.","80 Years",{"count":105,"type":21},20,"INTERVENTIONAL",[108],"NA",[26,110],"Liver Ablation","2026-03-04",{"date":113,"type":66},"2026-03-09",{"date":115,"type":21},"2026-03-16",{"date":117,"type":21},"2027-12-31",{"name":119,"class":73},"Fudan University",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":128,"targetDuration":129,"studyType":23,"phases":4,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":96},"100627190","italian-group-of-regenerative-and-occlusive-worldwide-used-techniques-of-hepatic-hypertrophy-100627190","NCT07445412","Italian Group of Regenerative and Occlusive Worldwide-used Techniques of Hepatic Hypertrophy","Italian Group of Regenerative and Occlusive Worldwide-used Techniques of Hepatic Hypertrophy - IGROWtoh","I-GROWtoh","Inclusion Criteria:\n\n* Patients aged 18 or older\n* Obtaining informed consent\n* Patients with liver neoplasia (benign or malignant) and with a future liver remnant volume deemed insufficient (\\\u003C20%-40%) by the local multidisciplinary team\n\nExclusion Criteria:\n\n* pregnant or breastfeeding woman",{"count":20,"type":21},"5 Years","The goal of this national mutlticenter observational study is to learn and describe trends over time in the use of techniques for inducing hepatic hypertrophy in Italy. Patients will be treated according to the current clinical practice of the participating centers and will be observed from the moment of recruitment and throughout their stay. Information on vital status will be collected, as far as possible, for up to 5 years after surgery in order to record any events that occur in a timely manner. There are also plans to retrospectively collect data on patients who underwent hypertrophic techniques in the previous 10 years, in order to establish a historical cohort for each center that can be used for comparison with the prospective cohort.",[132,26,133,134],"Liver Tumours","Liver Resection","Liver Hypertrophy","2026-02-25",{"date":137,"type":66},"2026-03-03",{"date":139,"type":66},"2024-10-22",{"date":141,"type":21},"2040-04",{"name":143,"class":73},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":106,"phases":154,"briefSummary":157,"conditions":158,"keywords":172,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":96},"100624518","phase-1-ebnk-001-allogeneic-nk-cells-with-low-dose-il-15--pembrolizumab-in-advanced-solid-tumors-100624518","NCT07410676","EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors","An Open-Label Phase 1\u002F2 Study of EBNK-001, an Allogeneic Natural Killer (NK) Cell Therapy Administered After Cyclophosphamide\u002FFludarabine Lymphodepletion With Low-Dose Interleukin-15, With or Without Pembrolizumab, in Participants With Advanced Solid Tumors","EBNK-ST-001","Inclusion Criteria:\n\n* Age ≥18 years.\n* Histologically confirmed advanced\u002Fmetastatic solid tumor that is relapsed\u002Frefractory after standard therapy (or no standard therapy available).\n* Measurable disease per RECIST v1.1 (or iRECIST if applicable).\n* ECOG performance status 0-1 (or 0-2 as allowed).\n* Adequate organ function (thresholds modeled on NK protocols):\n* Platelets ≥ 75,000\u002FµL; hemoglobin ≥ 9 g\u002FdL; ANC ≥ 1,000\u002FµL (unsupported by growth factors\u002Ftransfusions as defined).\n* eGFR ≥ 60 mL\u002Fmin\u002F1.73m².\n* AST\u002FALT ≤ 3× ULN.\n* Oxygen saturation ≥ 90% on room air (with PFT requirements if indicated).\n* LVEF ≥ 40% (by ECHO\u002FMUGA\u002FCMR).\n* If brain metastases are present, they must be stable for a defined period (example: ≥3 months) and not requiring escalating steroids.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding.\n* Any condition requiring systemic immunosuppression (e.g., \\>5 mg prednisone\u002Fday or equivalent) during dosing window (topical\u002Finhaled may be allowed).\n* Active autoimmune disease requiring systemic immunosuppression.\n* Uncontrolled bacterial, fungal, or viral infection.\n* Receipt of investigational agent within 28 days before first study drug.\n* Live vaccine within 6 weeks prior to lymphodepletion.\n* Known HIV positivity or active hepatitis B\u002FC with detectable viral load (protocol may allow chronic asymptomatic hepatitis depending on risk plan).\n* Known allergy to investigational product components (example: albumin\u002Fhuman or DMSO).\n* Any medical\u002Fsocial condition likely to interfere with study compliance or increase risk.",{"count":153,"type":21},83,[155,156],"PHASE1","PHASE2","This Phase 1\u002F2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of EBNK-001 (allogeneic NK cells) given after lymphodepleting cyclophosphamide\u002Ffludarabine (CY\u002FFLU) and supported with low-dose IL-15, administered either alone or in combination with pembrolizumab in adults with advanced\u002Fmetastatic solid tumors. The study will determine a recommended Phase 2 dose (RP2D) and explore signals of clinical activity using RECIST-based response criteria.",[159,160,161,162,27,163,164,165,166,167,26,168,169,170,171],"Cancer","Sarcoma","Leukaemia","Breast Cancer (Locally Advanced or Metastatic)","Colorectal Cancer","Melanoma (Skin Cancer)","Bladder Cancer","Kidney Cancer","Pancreatic Cancer Metastatic","Ovarian Cancer","Esophageal Cancer","Glioblastoma","Non-Melanoma Skin Cancer",[173,174,175,176,177,178,179,180,181,171,182,165,183,184,185,169],"Natural killer cells","NK cell therapy","Solid tumors","IL-15","Breast Cancer","Lung and Bronchus Cancer","Prostate Cancer","Colorectal (Colon and Rectal) Cancer","CAR-T","Melanoma","Kidney (Renal Cell and Renal Pelvis) Cancer","Pancreatic Cancer","Stomach (Gastric) Cancer","2026-02-14",{"date":188,"type":66},"2026-02-18",{"date":190,"type":66},"2026-02-01",{"date":192,"type":21},"2029-12-21",{"name":194,"class":73},"Essen Biotech",{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":203,"conditions":204,"keywords":205,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":96},"100616293","intra-procedural-spectral-ct-for-image-guided-embolization-and-ablation-in-interventional-oncology-100616293","NCT07303725","Intra-procedural Spectral CT for Image-guided Embolization and Ablation in Interventional Oncology","Inclusion criteria:\n\n1. Age \\> or = 18 years\n2. Tumor in an area without prior surgical or ablative therapy\n3. At least 1 tumor greater than 1.5 cm in greatest diameter\n\nExclusion criteria:\n\n1. Not eligible for indicated procedure.\n2. BMI \\> 35\n3. Prior surgery.",{"count":202,"type":21},30,"This is a pilot study to evaluate the feasibility, image quality, and procedural utility of a novel spectral CT technique using Canon Medical's 4D CT system during image-guided interventional oncology procedures",[26,31],[206],"spectral CT","2025-12-18",{"date":209,"type":66},"2025-12-26",{"date":211,"type":66},"2025-02-01",{"date":213,"type":21},"2026-09-01",{"name":215,"class":73},"Palo Alto Veterans Institute for Research"]